MedTrace Logo

A Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants in China

NCT05547243 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 350

Last updated 2023-02-14

No results posted yet for this study

Summary

This is a cohort study to evaluate safety and immunogenicity of COVID-19 mRNA Vaccine, Bivalent (LVRNA021) in participants aged 18 years and over in China

Conditions

Interventions

BIOLOGICAL

SARS-CoV-2 mRNA Vaccine, Bivalent Low dose

50μg/dose

BIOLOGICAL

SARS-CoV-2 mRNA Vaccine, Bivalent High dose

100μg/dose

DRUG

Placebo

Saline solution

Sponsors & Collaborators

  • Ningbo Rongan Biological Pharmaceutical Co., Ltd.

    collaborator INDUSTRY

  • The First Affiliated Hospital of Bengbu Medical University

    collaborator OTHER

  • AIM Vaccine Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Huan Zhou · The First Affiliated Hospital of Bengbu Medical University

  • Qiang Wu · The First Affiliated Hospital of Bengbu Medical University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-09-26
Primary Completion
2022-12-23
Completion
2024-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05547243 on ClinicalTrials.gov